期刊文献+

索拉菲尼对结肠癌Ht-29细胞增殖与凋亡影响及其机制的研究 被引量:2

Proliferation and Apoptosis Effect of Sorafenib on Colon Cancer Ht-29 Cells
下载PDF
导出
摘要 目的:研究索拉菲尼对结肠癌Ht-29细胞生长抑制作用,观察其对bax、bcl-2mRNA表达的影响。方法:MTT法测定索拉菲尼对Ht-29细胞株生长抑制率,Hoechst荧光染色观察细胞凋亡及形态的变化,Realtime-PCR检测bcl-2、bax mRNA表达情况。结果:索拉菲尼对Ht-29细胞株有生长抑制作用及促凋亡作用,拉菲尼处理后的Ht-29细胞中bcl-2 mRNA表达均较空白对照组降低,baxmRNA表达逐渐增强。结论:索拉菲尼可明显抑制荷Ht-29细胞增殖并诱导其凋亡,其作用机制可能与调控癌基因及凋亡基因表达有关。 OBJECTIVE: To investigate the effects of sorafenib on the proliferation and apoptosis of colon cancer Ht-29 cells. METHODS: Growth inhibition of Ht-29 cells by different concentrations of sorafenibwas evaluated by MTT assay. The effects of sorafenib on the apoptotic morphological changes were analyzed by Hoechst 33258 staining.The expressions of bcl-2, bax of Ht-29 cells treated with different concentrations of sorafenibwas were detected by Realtime-PCR. RESULTS: Sorafenib could had significantly inhibitory action on growth and apoptosis of Ht-29 cells, bcl-2 expressions of Ht-29 cells treated with different concentrations of sorafenib were significantly lower than the control group, while the bax expressions significantly upregulated, and the effects appeared to be dose-related (P〈0.05). CONCLUSION: Sorafenib could inhibit proliferation and induce apoptosis of colon cancer Ht-29 cells and has a great correlativity to the expressions of related oncogene and apoptosis- related genes.
出处 《中国医学装备》 2014年第B12期114-114,共1页 China Medical Equipment
关键词 索拉菲尼 HT-29 BAX BCL-2 Sorafenib Ht-29 bax bcl-2
  • 相关文献

参考文献4

二级参考文献45

  • 1樊嘉,徐泱,周俭.国内肝移植进展及展望[J].国外医学(消化系疾病分册),2005,25(1):3-5. 被引量:15
  • 2刘旭霞.临床护理路径在肝癌介入治疗中的应用[J].临床护理杂志,2006,5(3):39-40. 被引量:8
  • 3吴永娟,唐光才,李玉伟.肝癌介入治疗的研究进展[J].医学综述,2007,13(3):235-237. 被引量:5
  • 4周斌,徐光,戴社教,刘振堂.原发性肝癌介入治疗后疗效影响因素的分析[J].实用放射学杂志,2007,23(2):220-222. 被引量:18
  • 5Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005,(02):74-108.
  • 6Thompson MD,Monga SP. WNT/beta-catenin signaling in liver health and disease[J].{H}HEPATOLOGY,2007,(05):1298-1305.
  • 7Flaherty KT. Sorafenib:delivering a targeted drug to the right targets[J].{H}EXPERT REVIEW OF ANTICANCER THERAPY,2007,(05):617-626.
  • 8Hampton T. Cancer drug trials show modest benefit:drugs target liver,gastric,head and neck cancers[J].{H}JAMA:the Journal of the American Medical Association,2007,(03):273-275.
  • 9Liu L,Cao Y,Chen C. Sorafenib blocks the Raf/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].{H}CANCER RESEARCH,2006,(24):11851-11858.
  • 10Wilhelm SM,Carter C,Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].{H}CANCER RESEARCH,2004,(19):7099-7109.

共引文献21

同被引文献44

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部